加载中
NASDAQHealthcareBiotechnology
最新数据
US$251.38
−US$8.48 · -3.26%
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
收盘时
US$251.38
−US$8.48 · -3.26%
盘后
US$251.38
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
日内区间
当前US$251.38
52周区间
当前US$251.38
盘中时间采用ET。市场数据可能有所延迟。
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
日内区间
当前US$251.38
52周区间
当前US$251.38
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 855.3万 USD | 244.7万 USD | — | — |
| 销货成本 | 14万 USD | 1.52亿 USD | 8676.6万 USD | 1.54亿 USD | — |
| 毛利 | −14万 USD | −1.44亿 USD | −8431.9万 USD | −1.54亿 USD | — |
| 研究与开发 | 2.67亿 USD | 1.52亿 USD | 8676.6万 USD | 1.55亿 USD | 1.2亿 USD |
| 销售、一般及管理费用 | 5908.3万 USD | 5630.5万 USD | 4205.4万 USD | 5954.6万 USD | 4707.5万 USD |
| 营业费用 | 3.26亿 USD | 5630.5万 USD | 4205.4万 USD | 6054.6万 USD | 1.67亿 USD |
| 利息收入 | 2293万 USD | 1734.6万 USD | — | — | — |
| 折旧和摊销 | 14万 USD | 35.8万 USD | 43.2万 USD | 41.9万 USD | 18.2万 USD |
| 营业利润 | −3.26亿 USD | −2亿 USD | −1.26亿 USD | −2.15亿 USD | −1.67亿 USD |
| 净利润 | −3.03亿 USD | −1.83亿 USD | −1.23亿 USD | −2.14亿 USD | −1.67亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.11亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB2.25亿0.12%1853亿 USD0.03%US$288.16-0.46%
iShares Russell 2000 ETFIWM1.71亿0.22%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap Value ETFVBR1.34亿0.20%682亿 USD0.05%US$234.71+0.12%
State Street SPDR S&P Biotech ETFXBI1.09亿1.11%98.74亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF1.07亿0.11%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO6033.51万0.43%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB5298.08万0.49%108.2亿 USD0.44%US$204.26-1.08%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
